In the wake of the recent unearthing of major illegal trade practices including recycling of expired drugs by certain pharmaceutical traders in Chennai, the Health Department of Tamil Nadu Government has decided to enforce the Drugs & Cosmetics Act and Rules strictly in the state.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, announced a clinical and regulatory update on its lead product candidate, picoplatin. Following a detailed analysis of primary and updated data from the phase 3 SPEAR study of picoplatin in small cell lung cancer (SCLC) and an evaluation of the ongoing New Drug Application (NDA) process with the US Food and Drug Administration (FDA), the company has decided to suspend its efforts to obtain regulatory approval for picoplatin in SCLC at this time.
The National Institutes of Health (NIH) announced that it is creating a public database that researchers, consumers, health care providers, and others can search for information submitted voluntarily by genetic test providers. The Genetic Testing Registry (GTR) aims to enhance access to information about the availability, validity, and usefulness of genetic tests.
A two-day symposium on clinical trial 'CLINICON 2010' will be held at Narayana Health City in Bangalore from March 26 to 27, 2010. The event will help bring together experts in the field of clinical research.
The next Indian Pharmaceutical Association Convention (IPA Convention 2011) will be held at Indore in Madhya Pradesh in April next year. This was announced by the outgoing president of IPA Dr B Suresh at the valedictory session of the IPA Convention 2010 held in Chennai last week.
Entailing the ongoing controversy over the recognition of Master of Pharmacy (MS) programme offered by National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Pharmacy Council of India (PCI) has come out with a clarification that the NIPER's MS programme has not been specifically commented anytime by the council and is not an issue under the consideration of the body.
March 23, 2010 (Atlanta, Georgia) — An unexplained bias against sending women to the cath lab may be the reason women are about twice as likely as men to die within a month of an MI, a study from the European Cardiology Audit and Registration Data Standards (CARDS) data set shows.
Piramal Healthcare and Cipla signed a definitive agreement for purchase of all intellectual property rights in India related to i-pill brand of Cipla. The deal was sealed for an aggregate consideration of Rs 95 crore. i-pill brand features in the top-300 pharmaceutical products and had sales of Rs 30.92 crore as per ORG IMS for the last twelve months.
Even as the dust is yet to settle down over the HPV vaccine trial and death of three tribal girls in Andhra Pradesh, records showed that the total number of deaths among the clinical trial subjects, though not officially termed as part of the trials, are on the increase in India.
Bangalore, Mar, 23, 2010: Syngene International, a subsidiary of Biocon has entered into a discovery and development collaboration with Endo Pharmaceuticals, USA to develop novel biological therapeutic molecules against cancer.
Under the agreement Endo will retain all rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo.